• The document is an earnings presentation for Q1 FY27 (Quarter ended 30th June 2026) submitted to the stock exchanges, accompanied by details for an earnings call. The event is an earnings call to discuss the company's operational and financial performance for the quarter.
  • The earnings call is scheduled for 14th August 2026 at 5:30 PM IST.
  • The stated purpose of the call is to discuss the operational and financial performance of the company.
  • The management participants for the call will include Mr. Rajeev Nannapaneni (Vice Chairman and Chief Executive Officer), Mr. Amit Parekh (Chief Financial Officer), Mr. Rajesh Chebiyam (Executive Vice President, Crop Health Sciences), and Mr. Rajeev Menon (Lead, Investor Relations).
  • The document enclosed is the full earnings presentation deck. A dial-in link and numbers are provided for access to the call.
  • The document includes extensive standard disclaimer language stating it contains forward-looking statements and is for information purposes only, clarifying it is not an offer to sell securities.

Financial Highlights from Presentation

  • The presentation discusses Q1 FY27 (Quarter ended 30th June 2026) results.
  • Consolidated Financial Performance:
  • Total Revenue: INR 7,944 Mn
  • EBITDA: INR 2,457 Mn (includes Other Income)
  • EBITDA Margin: 30.9% (vs. 25.1% in Q4FY26)
  • Profit After Tax (PAT): INR 2,065 Mn
  • PAT Margin: 26.0%
  • Earnings Per Share (EPS): INR 11.53 per share
  • Revenue Breakdown (INR Mn):
  • API Revenue: 667
  • Pharmaceutical Formulations:
  • Domestic: 1,364
  • International (Incl. profit share and subsidiaries): 4,771
  • Crop Health Sciences: 408
  • Other operating & non-operating income: 734
  • Profit Share from Associate: Profit share from associate Adcock Ingram Holdings Ltd. for Q1FY27 stood at INR 843 Mn. A note clarifies that as of July 2026, NATCO's stake in Adcock increased to 49%.
  • Business Update: The company received final approval for Eribulin Mesylate Injection from the U.S. FDA.
  • Product Pipeline: The presentation details the Key Para IV product pipeline for the USA, listing numerous products, brands, and therapeutic segments (e.g., Cancer, Diabetes, Migraine).

Additional Notes Section

  • The document is a formal submission letter to BSE and NSE, with the full earnings presentation attached as an enclosure.
  • The presentation contains extensive factual financial data for Q1 FY27, including revenue, profit, segment performance, and product pipeline details.
  • Logistical details for the earnings call are included: Date, Time, Dial-in Numbers for India, US, UK, Singapore, and a Diamond pass registration link.